An important announcement from one of our clients, Quest Diagnostics, offers a glance at how healthcare is becoming more and more personalized—and how the need to pool critical data to improve treatments can override competitive concerns. In this case, Quest and other organizations, including some of its major competitors, will work together to compile their proprietary data on thousands of gene mutations in certain types of breast cancers to help improve the search for new drugs and biological treatments for those cancers. The quest for cures can make strange bedfellows, but it’s a sign of the times that companies are realizing they can only get so far alone. The patients of the world should benefit.
For more details on the new BRCA Share project, read the full article on Reuters.com.
